| The Center For Gastrointestinal Disorders | |
|
1150 N 35th Avenue Suite 445 Hollywood FL 33021 | |
| (954) 961-7771 | |
| (954) 961-9633 |
| Full Name | The Center For Gastrointestinal Disorders |
|---|---|
| Speciality | Internal Medicine |
| Location | 1150 N 35th Avenue, Hollywood, Florida |
| Authorized Official Name and Position | Mark Lamet (PRESIDENT OWNER) |
| Authorized Official Contact | 9549617771 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| The Center For Gastrointestinal Disorders 1150 N 35th Avenue Suite 445 Hollywood FL 33021 Ph: (954) 961-7771 | The Center For Gastrointestinal Disorders 1150 N 35th Avenue Suite 445 Hollywood FL 33021 Ph: (954) 961-7771 |
| NPI Number | 1013004605 |
|---|---|
| Provider Enumeration Date | 10/06/2006 |
| Last Update Date | 08/07/2017 |
| Medicare PECOS PAC ID | 8628970423 |
|---|---|
| Medicare Enrollment ID | O20040122000826 |
News Archive
A common food additive, recently banned in France but allowed in the U.S. and many other countries, was found to significantly alter gut microbiota in mice, causing inflammation in the colon and changes in protein expression in the liver, according to research led by a University of Massachusetts Amherst food scientist.
KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.
Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.
Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalization for cardiac complications after completing treatment, according to research published online today in Blood, the journal of the American Society of Hematology. HL is a form of cancer of arising in the lymph nodes, and approximately 8,500 people were diagnosed with the disease in 2009, according to the American Cancer Society.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013004605 | NPI | - | NPPES |
| 064455200 | Medicaid | FL | |
| 10D0709356 | Other | CLIA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | (* (Not Available)) | Primary |
| Provider Name | Alvin Cohen |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1528130549 PECOS PAC ID: 8224037882 Enrollment ID: I20061207000417 |
News Archive
A common food additive, recently banned in France but allowed in the U.S. and many other countries, was found to significantly alter gut microbiota in mice, causing inflammation in the colon and changes in protein expression in the liver, according to research led by a University of Massachusetts Amherst food scientist.
KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.
Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.
Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalization for cardiac complications after completing treatment, according to research published online today in Blood, the journal of the American Society of Hematology. HL is a form of cancer of arising in the lymph nodes, and approximately 8,500 people were diagnosed with the disease in 2009, according to the American Cancer Society.
› Verified 4 days ago
| Provider Name | Mark Lamet |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1972554731 PECOS PAC ID: 0547162356 Enrollment ID: I20100715000418 |
News Archive
A common food additive, recently banned in France but allowed in the U.S. and many other countries, was found to significantly alter gut microbiota in mice, causing inflammation in the colon and changes in protein expression in the liver, according to research led by a University of Massachusetts Amherst food scientist.
KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.
Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.
Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalization for cardiac complications after completing treatment, according to research published online today in Blood, the journal of the American Society of Hematology. HL is a form of cancer of arising in the lymph nodes, and approximately 8,500 people were diagnosed with the disease in 2009, according to the American Cancer Society.
› Verified 4 days ago
| Provider Name | Ari Lamet |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1871723528 PECOS PAC ID: 7012200116 Enrollment ID: I20160727001335 |
News Archive
A common food additive, recently banned in France but allowed in the U.S. and many other countries, was found to significantly alter gut microbiota in mice, causing inflammation in the colon and changes in protein expression in the liver, according to research led by a University of Massachusetts Amherst food scientist.
KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.
Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.
Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalization for cardiac complications after completing treatment, according to research published online today in Blood, the journal of the American Society of Hematology. HL is a form of cancer of arising in the lymph nodes, and approximately 8,500 people were diagnosed with the disease in 2009, according to the American Cancer Society.
› Verified 4 days ago
| Provider Name | Heather L Perkowski |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538703376 PECOS PAC ID: 5092149955 Enrollment ID: I20191231000430 |
News Archive
A common food additive, recently banned in France but allowed in the U.S. and many other countries, was found to significantly alter gut microbiota in mice, causing inflammation in the colon and changes in protein expression in the liver, according to research led by a University of Massachusetts Amherst food scientist.
KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.
Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.
Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalization for cardiac complications after completing treatment, according to research published online today in Blood, the journal of the American Society of Hematology. HL is a form of cancer of arising in the lymph nodes, and approximately 8,500 people were diagnosed with the disease in 2009, according to the American Cancer Society.
› Verified 4 days ago
News Archive
A common food additive, recently banned in France but allowed in the U.S. and many other countries, was found to significantly alter gut microbiota in mice, causing inflammation in the colon and changes in protein expression in the liver, according to research led by a University of Massachusetts Amherst food scientist.
KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.
Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.
Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalization for cardiac complications after completing treatment, according to research published online today in Blood, the journal of the American Society of Hematology. HL is a form of cancer of arising in the lymph nodes, and approximately 8,500 people were diagnosed with the disease in 2009, according to the American Cancer Society.
› Verified 4 days ago
The Family Practice Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3816 Hollywood Blvd, Suite 102, Hollywood, FL 33021 Phone: 954-987-2900 Fax: 954-987-2986 | |
Path Medical Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2544 N State Road 7, Hollywood, FL 33021 Phone: 954-735-6584 Fax: 954-735-6589 | |
Lifeline Health, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1311 N Federal Hwy # 1, Hollywood, FL 33020 Phone: 888-202-6052 | |
Coral West Health Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 11011 Sheridan St Ste 205, Hollywood, FL 33026 Phone: 954-404-6430 Fax: 954-404-6362 | |
Exablate Of North Dade County Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3440 Hollywood Blvd, Venture Corporate Center I, Suite 110, Hollywood, FL 33021 Phone: 281-820-7900 Fax: 281-820-7925 | |
Broward Medical Center Group, Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5920 Johnson St, Ste 104, Hollywood, FL 33021 Phone: 954-985-0985 |